Ones To Watch News
Refine Search
Pharmaceutical
A French biotech company claiming to have the first drug that treats the root cause of type 2 diabetes has completed a Series A funding round. 23 January 2023
Biotechnology
New Jersey, USA-based Outlook Therapeutics has announced the appointments of Dr Surendra Sharma as senior vice president, medical affairs, and Glen Olsheim as executive director, commercial excellence. 23 January 2023
Biotechnology
Waltham, Massachusetts, USA-based biotech Morphic Therapeutic announced I a Securities and Exchange Commission (SEC) filing that Johnson & Johnson subsidiary Janssen Pharmaceuticals has elected to terminate the research collaboration and option agreement between the companies dated December 30, 2020, and as further expanded and amended. 23 January 2023
Biotechnology
Chinese biotech company BeiGene has announced that the US Food and Drug Administration (FDA) has approved Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). 20 January 2023
Pharmaceutical
Massachusetts, USA-based psychoactive medicine specialist Sensorium Therapeutics has appointed Jeffrey Brown as chief scientific officer. 19 January 2023
Biotechnology
Following on from European Commission (EC) approvals in November, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for Brukinsa (zanubrutinib) in Great Britain. 19 January 2023
Biotechnology
Sino-American biotech BeiGene saw its shares rise 3.5% to 160.51 renminbi, after it announced that the National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include four new indications for its PD-1 inhibitor tislelizumab. 19 January 2023
Biotechnology
EVOQ Therapeutics and fellow USA-based Amgen today announced they are advancing their ongoing license and collaboration agreement for the discovery and development of novel therapeutics including the receipt of a milestone payment and expansion of the scope of collaboration to include a total of three indications in autoimmune disorders. 18 January 2023
Pharmaceutical
Sygnature Discovery, which claims to be the UK’s largest independent drug discovery expert and research partner, revealed that it has acquired Scotland-based SB Drug Discovery, a provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications. 18 January 2023
Biotechnology
Privately-held US cancer drug biotech Elicio Therapeutics has entered into a definitive merger agreement with Angion Biomedica under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. 18 January 2023
Biotechnology
Spanish plasma-derived medicines specialist Grifols has announced that its plasma-protein based fibrin sealant (FS) for controlling surgical bleeding obtained positive top-line results from a Phase IIIb clinical trial in pediatric patients. 17 January 2023
Biotechnology
California, USA-based clinical-stage biopharmaceutical company 89bio’s pegazofermin has potential to become one of the major players in the dyslipidemia space if it is successful in Phase III clinical trials, says analyst. 17 January 2023
Biotechnology
Rachel Abbott has been appointed chief scientific officer of Pan Cancer T, a biotech spin-off from the Erasmus University Medical Center, in the Netherlands. 17 January 2023
Biotechnology
French biotech Abionyx Pharma has reported that the pilot Phase IIa trial of CER-001 as a treatment for septic patients at high risk of developing acute kidney injury (AKI) met its primary objective. 16 January 2023
Biotechnology
London-listed Finnish biotech firm Faron Pharmaceuticals saw its share rise 11.4% to 351.00 pence this morning after it released positive early-stage clinical data on its novel precision cancer immunotherapy candidate. 16 January 2023
Pharmaceutical
A Phase III trial miss has hollowed out the share price of Israel-headquartered clinical-stage diabetes specialist Oramed Pharmaceuticals. 13 January 2023
Pharmaceutical
US a multi-asset longevity biotech Cambrian Biopharma yesterday unveiled its latest pipeline company, as Isterian Biotech. emerged from stealth, headquartered in New York. 13 January 2023
Biotechnology
The US Food and Drug Administration’s (FDA) recent approval of TG Therapeutics’ Briumvi (ublituximab) against relapsing forms of multiple sclerosis (MS) is welcome news for the company after suffering a major setback in 2022 when the FDA extended its review of Briumvi by three months. 13 January 2023
Biotechnology
Pittsburgh, USA-based clinical-stage biotech Lipella Pharmaceuticals’ shares rose as much as 76% to $5.48, after it announced positive trial results with its bladder disease candidate. 12 January 2023
Pharmaceutical
British biotech Pheno Therapeutics has announced a licensing deal with Belgium’s largest drugmaker UCB, focusing on the science of remyelination. 11 January 2023
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze